NYSE:ENZ - Enzo Biochem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.16 +0.01 (+0.32 %)
(As of 11/20/2018 12:55 PM ET)
Previous Close$3.15
Today's Range$3.05 - $3.25
52-Week Range$3.01 - $9.87
Volume2,209 shs
Average Volume128,181 shs
Market Capitalization$145.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing ‘STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ENZ
Previous Symbol
CUSIPN/A
Phone212-583-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.12
Quick Ratio3.76

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$104.71 million
Price / Sales1.42
Cash FlowN/A
Price / CashN/A
Book Value$1.72 per share
Price / Book1.84

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-10,320,000.00
Net Margins-9.86%
Return on Equity-13.25%
Return on Assets-10.75%

Miscellaneous

Employees503
Outstanding Shares47,180,000
Market Cap$145.32 million
OptionableOptionable

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Tuesday, October, 16th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.06. The medical research company had revenue of $24.46 million for the quarter. Enzo Biochem had a negative return on equity of 13.25% and a negative net margin of 9.86%. View Enzo Biochem's Earnings History.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Thursday, December 6th 2018. View Earnings Estimates for Enzo Biochem.

Has Enzo Biochem been receiving favorable news coverage?

Headlines about ENZ stock have been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enzo Biochem earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani Ph.D., Co-Founder, Chairman, CEO & Sec. (Age 75)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 68)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 52)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 60)
  • Dr. Dieter Schapfel, Chief Medical Director (Age 55)

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different of retail and institutional investors. Top institutional investors include Evermore Global Advisors LLC (9.67%), Evermore Global Advisors LLC (7.76%), Renaissance Technologies LLC (6.28%), Dimensional Fund Advisors LP (4.33%), The Manufacturers Life Insurance Company (4.19%) and Acadian Asset Management LLC (0.97%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Bruce A Hanna, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Evermore Global Advisors LLC, GSA Capital Partners LLP, Renaissance Technologies LLC, AQR Capital Management LLC, TIAA CREF Investment Management LLC, Acadian Asset Management LLC and Corrado Advisors LLC. Company insiders that have sold Enzo Biochem company stock in the last year include Barry W Weiner and Elazar Rabbani. View Insider Buying and Selling for Enzo Biochem.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Algert Global LLC, Assenagon Asset Management S.A., Marathon Capital Management, Bridgeway Capital Management Inc., Dimensional Fund Advisors LP, Strs Ohio and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna and Elazar Rabbani. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $3.17.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $145.32 million and generates $104.71 million in revenue each year. Enzo Biochem employs 503 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is http://www.enzo.com.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.


MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel